Snipr Biome takes aim at antibiotic resistant bacteria in phase I trial

Danish biotech company Snipr Biome, which is developing a new type of antibiotics using the gene-editing tool CRISPR, is sending its first candidate to clinic. ”It’s a huge day for us,” says CEO Christian Grøndahl.
Photo: Wolfgang Kumm/AP/Ritzau Scanpix
Photo: Wolfgang Kumm/AP/Ritzau Scanpix
by andreas lønstrup, translated by daniel pedersen

Danish biotech firm Snipr Biome announced on Wednesday that the first dose had been administered in a phase I trial with a potentially preventive treatment against E.coli infections in the gut.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading